BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

The heyday of digital health may not yet even be on the horizon, but investments in the field are certainly starting to hit the radar in the areas most likely to impact patients first --...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...Positive clinical data for the biotech’s CroFab antivenom to treat copperhead snake envenomation and its EKOS...
BioCentury | Jul 15, 2013
Company News

BTG, Ekos Corp. deal

...BTG completed its acquisition of medical device company Ekos for $180 million up front, plus up...
...up to $40 million in milestones (see BioCentury, May 27). BTG plc (LSE:BTG), London, U.K. Ekos Corp....
BioCentury | May 27, 2013
Finance

Highlights of weekly biotech stock moves

...device company Ekos Corp. for $180 million up front, plus up to $40 million in milestones. Ekos...
BioCentury | May 27, 2013
Company News

BTG, Ekos Corp., Nordion deal

...BTG announced a pair of deals last week with Nordion and Ekos. BTG will acquire TheraSphere...
...device company Ekos for $180 million up front, plus up to $40 million in milestones. Ekos...
...embolizing the blood vessels of hypervascular tumor and arteriovenous malformations. BTG plc (LSE:BTG), London, U.K. Ekos Corp....
BioCentury | May 24, 2013
Company News

BTG announces fundraising, deals

...Ekos Corp. (Bothell, Wash.) for $180 million up front, plus up to $40 million in milestones. Ekos...
Items per page:
1 - 8 of 8
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of...
BioCentury | Nov 22, 2019
Finance

DigiTx focuses on data in evolving landscape of digital health investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways. DigiTx Partners was launched...
BioCentury | Aug 31, 2019
Product Development

Digital dollars: financing for digital health

The heyday of digital health may not yet even be on the horizon, but investments in the field are certainly starting to hit the radar in the areas most likely to impact patients first --...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...Positive clinical data for the biotech’s CroFab antivenom to treat copperhead snake envenomation and its EKOS...
BioCentury | Jul 15, 2013
Company News

BTG, Ekos Corp. deal

...BTG completed its acquisition of medical device company Ekos for $180 million up front, plus up...
...up to $40 million in milestones (see BioCentury, May 27). BTG plc (LSE:BTG), London, U.K. Ekos Corp....
BioCentury | May 27, 2013
Finance

Highlights of weekly biotech stock moves

...device company Ekos Corp. for $180 million up front, plus up to $40 million in milestones. Ekos...
BioCentury | May 27, 2013
Company News

BTG, Ekos Corp., Nordion deal

...BTG announced a pair of deals last week with Nordion and Ekos. BTG will acquire TheraSphere...
...device company Ekos for $180 million up front, plus up to $40 million in milestones. Ekos...
...embolizing the blood vessels of hypervascular tumor and arteriovenous malformations. BTG plc (LSE:BTG), London, U.K. Ekos Corp....
BioCentury | May 24, 2013
Company News

BTG announces fundraising, deals

...Ekos Corp. (Bothell, Wash.) for $180 million up front, plus up to $40 million in milestones. Ekos...
Items per page:
1 - 8 of 8